Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parathyroid carcinoma.

Elizabeth A Mittendorf1, Christopher R McHenry

  • 1Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.

Journal of Surgical Oncology
|February 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

JAMA oncology·2026
Same author

ASO Visual Abstract: From Clinical Trial Awareness to Practice-Factors Associated with Intent to Omit Axillary Surgery Based on the SOUND Clinical Trial.

Annals of surgical oncology·2026
Same author

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

medRxiv : the preprint server for health sciences·2026
Same author

Multidisciplinary Clinics in Cancer-Models, Metrics, and Meaning: A Review.

The oncologist·2026
Same author

Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort.

JNCI cancer spectrum·2026
Same author

ASO Visual Abstract: Receipt of Combined Axillary Dissection and Nodal Irradiation Varies by Age.

Annals of surgical oncology·2026
Same journal

A Tale of Two Pathways: Same-Surgeon Versus Different-Surgeon Resection After Second Surgical Opinion.

Journal of surgical oncology·2026
Same journal

How I Do It: The Life and Work of a Rubber Band in Robotic Liver Parenchymal Transection.

Journal of surgical oncology·2026
Same journal

New Paradigms of Cancer Require New Language: A Qualitative Study Exploring Language for Non-Curative Non-Palliative Cancer Surgery.

Journal of surgical oncology·2026
Same journal

Performance of Survival Prediction Tools in Patients With Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis.

Journal of surgical oncology·2026
Same journal

Prognostic Factors for Patients Under 45 Undergoing Surgery for Colorectal Liver Metastases: A SEER Population-Based Study.

Journal of surgical oncology·2026
Same journal

Prehabilitation Prior to Colorectal Cancer Surgery: Impact and Implementation.

Journal of surgical oncology·2026
See all related articles

Parathyroid carcinoma, a rare cancer causing severe hypercalcemia, is linked to the HRPT2 gene. Genetic mutations impact diagnosis and management of this malignancy.

Area of Science:

  • Endocrinology
  • Oncology
  • Genetics

Background:

  • Parathyroid carcinoma is a rare malignancy, accounting for <1% of primary hyperparathyroidism (HPT) cases.
  • It often presents with severe hypercalcemia and associated kidney or bone disease in up to 50% of patients.
  • The exact etiology remains unknown, but the HRPT2 gene is implicated in its pathogenesis.

Purpose of the Study:

  • To summarize the genetic aspects of parathyroid carcinoma.
  • To review clinical manifestations and management principles.
  • To outline surgical therapy, adjuvant therapy indications, and hypercalcemia management strategies.

Main Methods:

  • Review of genetic factors, focusing on the HRPT2 tumor suppressor gene.
  • Analysis of clinical presentation and disease associations.

Related Experiment Videos

  • Summary of current therapeutic approaches, including surgery and pharmacotherapy.

    • Main Results:

    • The HRPT2 gene, encoding parafibromin, is a key factor in parathyroid carcinoma pathogenesis.
    • Inactivating germ-line mutations in HRPT2 have diagnostic and management implications.
    • Clinical manifestations include severe hypercalcemia and potential kidney/bone complications.

    Conclusions:

    • Understanding the genetic basis, particularly HRPT2 mutations, is crucial for parathyroid carcinoma diagnosis and management.
    • Comprehensive management involves surgery, potential adjuvant therapies, and agents like bisphosphonates and calcimimetics for hypercalcemia.
    • Further research into the etiology and genetic underpinnings of parathyroid carcinoma is warranted.